PASSAGE BIO

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

PHILADELPHIA, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders (CNS), today announced the expansion of its pipeline and provided a progress update on its three clinical programs.

Passage Bio Announces Pipeline Expansion and Clinical Program Update

New York, New York--(Newsfile Corp. - November 30, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street , is investigating whether certain officers and directors of Passage Bio, Inc. (NASDAQ: PASG) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own PASG please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. ...

Moore Kuehn, PLLC Encourages Investors of Passage Bio, Inc. to Contact Law Firm

PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee.

Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q3 2021 Results - Earnings Call Transcript

PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today reported financial results for the third quarter ended September 30, 2021 and provided recent business highlights.

Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in two upcoming conferences in October:

Passage Bio to Participate in Upcoming October Conferences

PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported that Maxine Gowen, Ph.D., has been appointed chairwoman of the board of directors for the company, effective August 31.

Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors

PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive officer of Passage Bio, will participate in a virtual panel presentation, titled “What's Next for Neurodegenerative Diseases,” at the upcoming Citi 16th Annual BioPharma Virtual Conference, September 8-10, 2021.

Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference

Passage Bio, Inc. (PASG) Bruce Goldsmith on Q2 2021 Results - Earnings Call Transcript

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, acknowledges today with great sorrow that Tadataka (Tachi) Yamada, M.D., founder and chairman of the board for Passage Bio, passed away unexpectedly on August 3, 2021.

Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive officer of Passage Bio, will participate in a virtual panel presentation at the upcoming 12th Annual Wedbush PacGrow Healthcare Virtual Conference, taking place on August 10-12, 2021.

Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference

Chief Commercial Officer, Chief Financial Officer and Chief Medical Officer to focus on driving company growth and advancing robust pipeline of transformative therapies for patients with CNS disorders Chief Commercial Officer, Chief Financial Officer and Chief Medical Officer to focus on driving company growth and advancing robust pipeline of transformative therapies for patients with CNS disorders

Passage Bio Announces Key Executive Appointments

Passage Bio (NASDAQ: PASG) shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $29 price target. The firm said the company's gene therapy platform and UPenn collaboration will create significant value for investors with multiple inflection events approaching in the next 6-12 months.

Why Passage Bio Shares Are Trading Higher Today

Passage Bio has failed considerably since I last covered it. They have also started or are about to start three trials.

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the election of Derrell D. Porter, M.D., to its board of directors and his appointment to the Audit Committee, effective as of May 27, 2021, the date of Passage Bio's Annual Meeting of Stockholders. Dr. Porter is founder and chief executive officer of Cellevolve Bio, a cell therapy company focused on transforming investigational CNS, oncology and transplant therapies into commercial products.

Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio

PHILADELPHIA, May 11, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, announced today the presentation by its collaborator University of Pennsylvania's Gene Therapy Program (GTP) of a digital poster at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Gourav Roy Choudhury, Ph.D., a senior research investigator at GTP, will report on the development and utility of a novel Arylsulfatase A-deficient mouse model in reproducing key aspects of human metachromatic leukodystrophy (MLD) neuropathology to enable evaluation of efficacy of adeno-associated virus (AAV) gene therapy. Preliminary findings showed the administration of Passage Bio's gene therapy candidate PBML04 (AAVhu68.GTP-207) significantly reduced the neurological deficits of MLD in this model.

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

Focus to be on frontotemporal dementia with granulin mutations Focus to be on frontotemporal dementia with granulin mutations

Passage Bio to Host Virtual R&D Event on May 17

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q1 2021 Results - Earnings Call Transcript

PHILADELPHIA, May 05, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today reported financial results for the first quarter ended March 31, 2021 and provided recent business highlights.

Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights

PHILADELPHIA, April 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 5, 2021 to report its first quarter 2021 financial results and discuss recent business highlights.

Passage Bio to Report First Quarter 2021 Financial Results on May 5, 2021

- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options

Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease

Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Passage Bio (PASG)

– PBGM01 advancement to clinical development represents key milestone for Passage Bio as a clinical-stage company –

Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis

PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in three upcoming virtual investor conferences in April:

News for PASSAGE BIO Stock (PASG)